Discuss This ICD-10 Code Read Blog Posts

ICD-10: E71.440

Ruvalcaba-Myhre-Smith syndrome

Additional Information

Description

Ruvalcaba-Myhre-Smith syndrome, classified under ICD-10 code E71.440, is a rare genetic disorder characterized by a combination of distinct clinical features. This syndrome is part of a broader category of disorders known as "disorders of amino-acid metabolism," specifically involving the metabolism of branched-chain amino acids.

Clinical Features

Key Characteristics

Individuals with Ruvalcaba-Myhre-Smith syndrome typically present with a range of symptoms that may include:

  • Intellectual Disability: A significant aspect of the syndrome is cognitive impairment, which can vary in severity among affected individuals.
  • Facial Dysmorphism: Patients often exhibit distinctive facial features, which may include a broad forehead, prominent eyebrows, and a flat nasal bridge.
  • Skeletal Abnormalities: Many individuals have skeletal anomalies, such as scoliosis or other spinal deformities, which can impact mobility and overall health.
  • Growth Retardation: Affected individuals may experience delayed growth and development, leading to shorter stature compared to peers.
  • Neurological Issues: Some patients may have seizures or other neurological complications, which can further complicate their clinical management.

Additional Symptoms

Other potential manifestations of Ruvalcaba-Myhre-Smith syndrome can include:

  • Hearing Loss: Some individuals may experience varying degrees of hearing impairment.
  • Cardiac Anomalies: Congenital heart defects have been reported in some cases, necessitating careful monitoring and management.
  • Behavioral Issues: Behavioral problems, including autism spectrum features, may also be present, impacting social interactions and daily functioning.

Genetic Basis

Ruvalcaba-Myhre-Smith syndrome is believed to be caused by mutations in specific genes involved in amino acid metabolism. Genetic testing can help confirm the diagnosis, particularly in cases where clinical features are ambiguous.

Diagnosis and Management

Diagnosis typically involves a combination of clinical evaluation, family history assessment, and genetic testing. Management of the syndrome is multidisciplinary, focusing on:

  • Educational Support: Tailored educational programs to address cognitive challenges.
  • Physical Therapy: To improve mobility and manage skeletal issues.
  • Regular Monitoring: Ongoing assessments by healthcare professionals to address any emerging health concerns, including neurological and cardiac evaluations.

Conclusion

Ruvalcaba-Myhre-Smith syndrome is a complex condition requiring a comprehensive approach to care. Early diagnosis and intervention can significantly improve the quality of life for affected individuals. As research continues, further insights into the genetic underpinnings and potential therapies for this syndrome may emerge, offering hope for better management strategies in the future.

Clinical Information

Ruvalcaba-Myhre-Smith syndrome (RMSS), associated with the ICD-10 code E71.440, is a rare genetic disorder characterized by a distinct set of clinical presentations, signs, symptoms, and patient characteristics. This syndrome is primarily linked to mutations in the KMT2D gene, which plays a crucial role in chromatin remodeling and gene expression.

Clinical Presentation

Genetic Background

Ruvalcaba-Myhre-Smith syndrome is inherited in an autosomal dominant pattern, meaning that a mutation in just one copy of the KMT2D gene can lead to the disorder. The syndrome is often diagnosed in childhood or early adulthood, although some symptoms may not become apparent until later in life.

Common Signs and Symptoms

Patients with RMSS exhibit a variety of clinical features, which can vary significantly in severity and presentation. The most common signs and symptoms include:

  • Facial Dysmorphism: Characteristic facial features may include a broad forehead, prominent eyes, a flat nasal bridge, and a wide mouth. These features can lead to a distinctive appearance that may be recognized by healthcare professionals.

  • Developmental Delays: Many individuals with RMSS experience developmental delays, particularly in speech and motor skills. This can manifest as delayed walking or difficulty in communication.

  • Intellectual Disability: Cognitive impairment is common, with varying degrees of intellectual disability reported among affected individuals.

  • Skeletal Abnormalities: Patients may present with skeletal anomalies, including scoliosis, joint hypermobility, and other musculoskeletal issues.

  • Cardiac Anomalies: Congenital heart defects have been observed in some patients, necessitating careful cardiovascular evaluation.

  • Behavioral Issues: Some individuals may exhibit behavioral problems, including attention deficits or autism spectrum features.

  • Hypotonia: Reduced muscle tone (hypotonia) is frequently noted, which can affect motor development and coordination.

Additional Patient Characteristics

  • Age of Onset: Symptoms typically present in early childhood, although some features may not be recognized until later.

  • Gender Distribution: There is no significant gender bias reported in the prevalence of RMSS, affecting both males and females equally.

  • Family History: Given its genetic nature, a family history of similar symptoms or confirmed cases of RMSS may be present, particularly in families with known KMT2D mutations.

Conclusion

Ruvalcaba-Myhre-Smith syndrome is a complex genetic disorder with a range of clinical manifestations. The combination of distinctive facial features, developmental delays, intellectual disability, and potential cardiac and skeletal anomalies necessitates a multidisciplinary approach for diagnosis and management. Early intervention and supportive therapies can significantly improve the quality of life for affected individuals. As research continues, further insights into the genetic underpinnings and potential treatments for RMSS may emerge, offering hope for better outcomes in the future.

Approximate Synonyms

Ruvalcaba-Myhre-Smith syndrome, classified under the ICD-10 code E71.440, is a rare genetic disorder characterized by a combination of symptoms that can include intellectual disability, distinctive facial features, and skeletal abnormalities. Understanding the alternative names and related terms for this syndrome can be beneficial for healthcare professionals, researchers, and patients alike.

Alternative Names

  1. Ruvalcaba Syndrome: This is a shortened form of the full name and is commonly used in medical literature.
  2. Myhre Syndrome: Sometimes, the syndrome is referred to by the name of one of the researchers associated with its identification, which can lead to some confusion with other syndromes.
  3. Ruvalcaba-Myhre Syndrome: This name combines the surnames of the researchers who described the syndrome, emphasizing its dual identification.
  1. E71.4: This is the broader category under which Ruvalcaba-Myhre-Smith syndrome falls, encompassing other disorders related to disorders of amino-acid metabolism.
  2. Genetic Disorder: Ruvalcaba-Myhre-Smith syndrome is classified as a genetic disorder, indicating its hereditary nature.
  3. Intellectual Disability: A common symptom associated with this syndrome, highlighting the cognitive challenges faced by affected individuals.
  4. Skeletal Abnormalities: Refers to the physical manifestations of the syndrome, which can include various bone and joint issues.
  5. Facial Dysmorphism: This term describes the distinctive facial features often seen in individuals with the syndrome.

Conclusion

Ruvalcaba-Myhre-Smith syndrome is recognized by several alternative names and related terms that reflect its clinical characteristics and genetic basis. Understanding these terms is crucial for accurate diagnosis, treatment, and research into this rare condition. If you require further information or specific details about the syndrome, feel free to ask!

Diagnostic Criteria

Ruvalcaba-Myhre-Smith syndrome, classified under ICD-10 code E71.440, is a rare genetic disorder characterized by a combination of clinical features, including developmental delays, distinctive facial features, and skeletal abnormalities. The diagnosis of this syndrome typically involves a comprehensive evaluation based on clinical criteria, genetic testing, and the exclusion of other conditions. Below are the key criteria used for diagnosis:

Clinical Features

  1. Developmental Delays: Individuals often exhibit significant delays in reaching developmental milestones, including motor skills and speech. This is a hallmark of the syndrome and is often one of the first signs noted by caregivers.

  2. Distinctive Facial Features: Patients may present with specific facial characteristics, which can include:
    - A broad forehead
    - Hypertelorism (widely spaced eyes)
    - A flat nasal bridge
    - A prominent chin
    - Other dysmorphic features that may vary among individuals

  3. Skeletal Abnormalities: Common skeletal issues associated with Ruvalcaba-Myhre-Smith syndrome include:
    - Short stature
    - Limb deformities
    - Other skeletal dysplasias that may be identified through imaging studies

  4. Other Associated Symptoms: Additional symptoms may include hearing loss, cardiac anomalies, and other organ system involvement, which can vary widely among affected individuals.

Genetic Testing

  • Genetic Confirmation: Diagnosis can be confirmed through genetic testing, which may identify mutations in specific genes associated with the syndrome. Genetic counseling is often recommended for families to understand the implications of the diagnosis and the inheritance patterns.

Exclusion of Other Conditions

  • Differential Diagnosis: It is crucial to rule out other syndromes or conditions that may present with similar features. This may involve a thorough clinical evaluation and possibly additional genetic testing to exclude other genetic disorders.

Multidisciplinary Approach

  • Team Evaluation: Diagnosis often involves a multidisciplinary team, including pediatricians, geneticists, neurologists, and other specialists who can assess the various aspects of the syndrome and provide a comprehensive care plan.

In summary, the diagnosis of Ruvalcaba-Myhre-Smith syndrome (ICD-10 code E71.440) relies on a combination of clinical features, genetic testing, and the exclusion of other similar conditions. Early diagnosis and intervention can significantly improve the quality of life for affected individuals. If you have further questions or need more specific information, feel free to ask!

Treatment Guidelines

Ruvalcaba-Myhre-Smith syndrome, classified under ICD-10 code E71.440, is a rare genetic disorder characterized by a combination of intellectual disability, distinctive facial features, and various physical anomalies. Given its rarity, treatment approaches are often tailored to the individual needs of the patient, focusing on managing symptoms and improving quality of life. Below is an overview of standard treatment approaches for this syndrome.

Overview of Ruvalcaba-Myhre-Smith Syndrome

Ruvalcaba-Myhre-Smith syndrome is primarily caused by mutations in the KMT2D gene, which plays a crucial role in gene regulation and development. The syndrome manifests with a range of symptoms, including:

  • Intellectual disability: Varying degrees of cognitive impairment.
  • Distinctive facial features: Such as a broad forehead, prominent nose, and other dysmorphic traits.
  • Physical anomalies: These may include skeletal abnormalities, heart defects, and other organ-related issues.

Standard Treatment Approaches

1. Multidisciplinary Care

Given the complexity of Ruvalcaba-Myhre-Smith syndrome, a multidisciplinary approach is essential. This typically involves:

  • Pediatricians: To monitor overall health and development.
  • Geneticists: For genetic counseling and management of the syndrome.
  • Neurologists: To address any neurological issues that may arise.
  • Psychologists/Psychiatrists: For mental health support and cognitive therapies.

2. Therapeutic Interventions

a. Educational Support

Children with Ruvalcaba-Myhre-Smith syndrome often benefit from specialized educational programs tailored to their cognitive abilities. Individualized Education Plans (IEPs) can help address learning challenges and promote skill development.

b. Physical and Occupational Therapy

Physical therapy can assist in improving motor skills and coordination, while occupational therapy focuses on enhancing daily living skills. These therapies are crucial for fostering independence and improving quality of life.

c. Speech and Language Therapy

Many individuals with this syndrome may experience speech delays or difficulties. Speech therapy can help improve communication skills, which is vital for social interaction and personal development.

3. Medical Management

a. Regular Health Monitoring

Routine check-ups are essential to monitor for associated health issues, such as heart defects or endocrine problems. Early detection and management of these conditions can significantly improve outcomes.

b. Medications

While there is no specific medication for Ruvalcaba-Myhre-Smith syndrome, symptomatic treatments may be prescribed. This can include medications for managing behavioral issues, seizures, or other associated conditions.

4. Supportive Care

a. Family Support and Counseling

Families often face unique challenges when caring for a child with a rare syndrome. Support groups and counseling can provide emotional support and practical advice for managing daily challenges.

b. Community Resources

Accessing community resources, such as respite care and recreational programs, can provide additional support for families and enhance the quality of life for individuals with the syndrome.

Conclusion

While Ruvalcaba-Myhre-Smith syndrome presents various challenges, a comprehensive treatment approach that includes multidisciplinary care, therapeutic interventions, and supportive resources can significantly improve the quality of life for affected individuals. Ongoing research and awareness are crucial for developing more effective treatment strategies and support systems for those impacted by this rare genetic disorder. Regular follow-ups and tailored interventions remain key components in managing the syndrome effectively.

Related Information

Description

  • Rare genetic disorder
  • Combination of distinct clinical features
  • Disorders of amino-acid metabolism
  • Branched-chain amino acid metabolism involved
  • Intellectual disability common symptom
  • Facial dysmorphism typical feature
  • Skeletal abnormalities present
  • Growth retardation often occurs
  • Neurological issues can arise

Clinical Information

  • Autosomal dominant inheritance
  • Facial dysmorphism with broad forehead
  • Developmental delays in speech and motor skills
  • Intellectual disability with varying degrees
  • Skeletal abnormalities including scoliosis
  • Cardiac anomalies with congenital heart defects
  • Hypotonia with reduced muscle tone
  • Age of onset in early childhood
  • No significant gender bias reported

Approximate Synonyms

  • Ruvalcaba Syndrome
  • Myhre Syndrome
  • Intellectual Disability
  • Skeletal Abnormalities
  • Facial Dysmorphism

Diagnostic Criteria

  • Developmental delays in motor skills and speech
  • Broad forehead and hypertelorism are present
  • Flat nasal bridge and prominent chin occur
  • Short stature and limb deformities identified
  • Genetic testing confirms Ruvalcaba-Myhre-Smith syndrome
  • Other syndromes excluded through differential diagnosis
  • Multidisciplinary team evaluates and provides care plan

Treatment Guidelines

  • Multidisciplinary care is essential
  • Pediatricians monitor overall health
  • Geneticists manage the syndrome
  • Neurologists address neurological issues
  • Psychologists/Psychiatrists provide mental health support
  • Educational programs are tailored to individual needs
  • Physical therapy improves motor skills
  • Occupational therapy enhances daily living skills
  • Speech and language therapy is provided for communication
  • Regular health monitoring is crucial for associated conditions
  • Medications may be prescribed for symptoms
  • Family support and counseling are essential
  • Community resources provide additional support

Related Diseases

orofaciodigital syndrome XI acrofacial dysostosis Rodriguez type acrofacial dysostosis, Patagonia type chromosomal deletion syndrome chromosome 10q23 deletion syndrome chromosome 14q11-q22 deletion syndrome chromosome 15q25 deletion syndrome chromosome 16p11.2 deletion syndrome, 220-kb chromosome 16p12.1 deletion syndrome chromosome 16q22 deletion syndrome chromosome 18p deletion syndrome chromosome 22q11.2 deletion syndrome, distal chromosome 2p12-p11.2 deletion syndrome chromosome 2q31.2 deletion syndrome chromosome 3q13.31 deletion syndrome chromosome 3q29 microdeletion syndrome chromosome 4q21 deletion syndrome chromosome 5q12 deletion syndrome chromosome 6q11-q14 deletion syndrome chromosome 6q24-q25 deletion syndrome chromosome 19p13.13 deletion syndrome chromosomal duplication syndrome chromosome 16p11.2 duplication syndrome chromosome 16p13.3 duplication syndrome chromosome 17p13.3 duplication syndrome chromosome 17q12 duplication syndrome chromosome 17q21.31 duplication syndrome chromosome 1q21.1 duplication syndrome chromosome 22q11.2 microduplication syndrome chromosome 22q13 duplication syndrome Cole-Carpenter syndrome stromal dystrophy chromosome 3q29 microduplication syndrome chromosome 5p13 duplication syndrome Desbuquois dysplasia fibrochondrogenesis Kabuki syndrome Goldberg-Shprintzen syndrome MEDNIK syndrome Schimke immuno-osseous dysplasia Warsaw breakage syndrome ablepharon macrostomia syndrome ataxia with oculomotor apraxia type 3 lethal congenital contracture syndrome 1 anomalous left coronary artery from the pulmonary artery 3MC syndrome 1 3MC syndrome 2 XFE progeroid syndrome WHIM syndrome 1 obsolete hereditary motor and sensory neuropathy with agenesis of the corpus callosum alpha-methylacyl-CoA racemase deficiency ulnar-mammary syndrome ethylmalonic encephalopathy lethal congenital contracture syndrome 3 lethal congenital contracture syndrome 4 lymphoproliferative syndrome familial chronic myelocytic leukemia-like syndrome autosomal dominant Robinow syndrome 2 autosomal dominant Robinow syndrome 3 syndromic X-linked intellectual disability Lubs type syndromic X-linked intellectual disability 5 Prieto syndrome syndromic X-linked intellectual disability Hedera type syndromic X-linked intellectual disability 7 syndromic X-linked intellectual disability Siderius type Wilson-Turner syndrome syndromic X-linked intellectual disability Abidi type syndromic X-linked intellectual disability 14 X-linked intellectual disability-psychosis-macroorchidism syndrome Griscelli syndrome type 2 Griscelli syndrome type 3 hereditary neuropathy with liability to pressure palsies osteoporosis-pseudoglioma syndrome autosomal recessive pseudohypoaldosteronism type 1 X-linked hereditary ataxia spinocerebellar ataxia type 1 spinocerebellar ataxia type 2 spinocerebellar ataxia type 4 spinocerebellar ataxia type 7 spinocerebellar ataxia type 10 spinocerebellar ataxia type 11 spinocerebellar ataxia type 12 spinocerebellar ataxia type 13 obsolete spinocerebellar ataxia type 16 spinocerebellar ataxia type 17 autosomal dominant cerebellar ataxia, deafness and narcolepsy spinocerebellar ataxia type 18 spinocerebellar ataxia type 20 spinocerebellar ataxia type 23 spinocerebellar ataxia type 25 spinocerebellar ataxia type 26 spinocerebellar ataxia type 27 spinocerebellar ataxia type 29 spinocerebellar ataxia type 30 spinocerebellar ataxia type 31 spinocerebellar ataxia type 35 spinocerebellar ataxia type 36 spinocerebellar ataxia type 37 spinocerebellar ataxia type 38 spinocerebellar ataxia type 40 episodic ataxia type 3 episodic ataxia type 6 episodic ataxia type 7 episodic ataxia type 8 cerebellar ataxia, mental retardation and dysequlibrium syndrome nonprogressive cerebellar ataxia with mental retardation autosomal recessive spinocerebellar ataxia 10 CD3zeta deficiency janus kinase-3 deficiency MHC class I deficiency CD45 deficiency coronin-1A deficiency CD40 ligand deficiency lambda 5 deficiency immunoglobulin alpha deficiency developmental disorder of mental health obsolete neurological disorder popliteal pterygium syndrome familial juvenile hyperuricemic nephropathy pre-malignant neoplasm benign neoplasm cell type benign neoplasm bone benign neoplasm musculoskeletal system benign neoplasm nervous system benign neoplasm obsolete skeletal system benign neoplasm alpha chain disease mu chain disease dentatorubral-pallidoluysian atrophy homocarnosinosis acrofrontofacionasal dysostosis Baraitser-Winter syndrome Warburg micro syndrome Van Maldergem syndrome synpolydactyly MASA syndrome Simpson-Golabi-Behmel syndrome type 1 sclerosteosis scapuloperoneal myopathy renal-hepatic-pancreatic dysplasia pontocerebellar hypoplasia type 1A pontocerebellar hypoplasia type 1B pontocerebellar hypoplasia type 2A pontocerebellar hypoplasia type 2B pontocerebellar hypoplasia type 2E pontocerebellar hypoplasia type 4 pontocerebellar hypoplasia type 5 pontocerebellar hypoplasia type 6 pontocerebellar hypoplasia type 10 primary pigmented nodular adrenocortical disease omodysplasia congenital secretory chloride diarrhea 1 Meier-Gorlin syndrome autosomal dominant intellectual developmental disorder autosomal recessive intellectual developmental disorder syndromic X-linked intellectual disability mitochondrial complex V (ATP synthase) deficiency nuclear type 2 mitochondrial complex V (ATP synthase) deficiency nuclear type 3 CEDNIK syndrome ciliopathy acromelic frontonasal dysostosis Native American myopathy adenine phosphoribosyltransferase deficiency mitochondrial complex III deficiency nuclear type 2 acrofacial dysostosis Cincinnati type glycerol kinase deficiency mandibulofacial dysostosis with alopecia Hennekam syndrome orofaciodigital syndrome III orofaciodigital syndrome IV orofaciodigital syndrome V orofaciodigital syndrome VII orofaciodigital syndrome VIII acrofacial dysostosis autoimmune polyendocrine syndrome type 2 monogenic disease obsolete complex genetic disease obsolete physical disorder OBSOLETED TERM obsolete genetic disorder obsolete peripheral dysostosis lacrimoauriculodentodigital syndrome 1 complement factor I deficiency mulibrey nanism familial partial lipodystrophy obsolete arachnodactyly Farber lipogranulomatosis Costello syndrome Carney complex bulbospinal polio obsolete acroosteolysis hypermethioninemia familial medullary thyroid carcinoma proteasome-associated autoinflammatory syndrome 1 X-linked sideroblastic anemia with ataxia obsolete infantile onset spinocerebellar ataxia spondylocostal dysostosis congenital disorder of glycosylation type I congenital disorder of glycosylation type II 2-hydroxyglutaric aciduria cranioectodermal dysplasia glycogen storage disease XV congenital generalized lipodystrophy muscular dystrophy-dystroglycanopathy type B1 glycogen storage disease IX ABCD syndrome ADULT syndrome anauxetic dysplasia 1 bestrophinopathy Boomerang dysplasia brachyolmia childhood electroclinical syndrome variable age at onset electroclinical syndrome AGAT deficiency COX deficiency, infantile mitochondrial myopathy methylmalonic aciduria and homocystinuria type cblC methylmalonic aciduria and homocystinuria type cblD cerebral folate receptor alpha deficiency ornithine translocase deficiency serine deficiency PHGDH deficiency PSAT deficiency tyrosinemia type II tyrosinemia type III Chanarin-Dorfman syndrome coenzyme Q10 deficiency disease X-linked monogenic disease autosomal dominant disease autosomal recessive disease autosomal genetic disease cerebellar ataxia ataxia with oculomotor apraxia type 1 deafness-dystonia-optic neuronopathy syndrome X-linked myopathy with excessive autophagy adenylosuccinase lyase deficiency ARC syndrome neuroacanthocytosis choreaacanthocytosis midface dysplasia mitochondrial complex V (ATP synthase) deficiency nuclear type 1 polycystic liver disease pheochromocytoma spastic ataxia 1 schneckenbecken dysplasia non-syndromic X-linked intellectual disability Meckel syndrome juvenile polyposis syndrome multiple cutaneous and mucosal venous malformations peroxisomal acyl-CoA oxidase deficiency guanidinoacetate methyltransferase deficiency Kahrizi syndrome mucopolysaccharidosis IX urofacial syndrome pyrimidine metabolic disorder orotic aciduria CHARGE syndrome cranio-facial dystonia Marshall-Smith syndrome fibroma inclusion body myopathy with Paget disease of bone and frontotemporal dementia spinocerebellar ataxia type 5 infantile cerebellar-retinal degeneration triosephosphate isomerase deficiency IMAGe syndrome syndromic intellectual disability synucleinopathy adrenal gland pheochromocytoma conjunctival nevus cecum adenoma rectal adenoma spastic ataxia 2 spastic ataxia 3 spastic ataxia 4 spastic ataxia 7 spastic ataxia

Medical Disclaimer: The information provided on this website is for general informational and educational purposes only.

It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with questions about your medical condition.